After testing serum IL-37 levels in 84 MS patients and 75 healthy controls, Ebrahim Kouchaki et al. found IL-37 levels in MS patients were higher than in the control group (p < 0.001) [51]. This evidence concerns the gene IL37 and myeloid sarcoma.